-
Publication Venue For
-
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
2021
-
Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy.
2020
-
Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia..
34:3075-3076.
2020
-
Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection..
34:3055-3059.
2020
-
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials..
34:2430-2440.
2020
-
Hematopoietic stem cell transplantation for adults with T-cell lymphoblastic lymphoma: can we successfully step into the era of precision medicine?.
34:1213-1214.
2020
-
Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905..
34:1006-1016.
2020
-
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis..
33:2974-2978.
2019
-
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study..
33:2599-2609.
2019
-
Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome..
33:2746-2751.
2019
-
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy..
33:2393-2402.
2019
-
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy..
33:2266-2275.
2019
-
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia..
33:1835-1850.
2019
-
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies..
33:371-378.
2019
-
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials..
33:554-558.
2019
-
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms..
32:2352-2362.
2018
-
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time..
32:986-995.
2018
-
Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy..
32:353-363.
2018
-
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma..
31:625-636.
2017
-
Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma..
31:373-381.
2017
-
Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia..
30:2080-2083.
2016
-
Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide..
30:2102-2106.
2016
-
Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course..
30:1779-1780.
2016
-
JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma..
30:1311-1319.
2016
-
A functional polymorphism in the CEBPE gene promoter influences acute lymphoblastic leukemia risk through interaction with the hematopoietic transcription factor Ikaros..
30:1194-1197.
2016
-
Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium..
30:361-372.
2016
-
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia..
29:567-575.
2015
-
Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity..
28:1915-1918.
2014
-
Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson..
28:289-292.
2014
-
Associations between genome-wide Native American ancestry, known risk alleles and B-cell ALL risk in Hispanic children..
27:2416-2419.
2013
-
Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function..
27:170-182.
2013
-
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia..
27:113-117.
2013
-
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study..
26:2103-2113.
2012
-
Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies..
26:1686-1689.
2012
-
The vascular niche: home for normal and malignant hematopoietic stem cells..
26:54-62.
2012
-
Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL..
25:1459-1466.
2011
-
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720..
25:800-807.
2011
-
LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells..
24:1580-1587.
2010
-
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study..
24:1350-1356.
2010
-
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)..
24:320-334.
2010
-
Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis..
24:133-140.
2010
-
Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia..
22:2184-2192.
2008
-
Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.
2015